New Pill Shows Promise in Controlling Stubborn High Blood Pressure
A groundbreaking new pill called baxdrostat has shown significant promise in lowering blood pressure in individuals with chronic kidney disease, a condition that often makes it difficult to control high blood pressure. According to results from the FigHTN Phase 2 clinical trial, published by the American Heart Association on October 8, 2025, baxdrostat reduced systolic blood pressure by approximately 5 points when added to existing medications.
The study involved over 300 participants with chronic kidney disease and uncontrolled high blood pressure. Researchers found that not only did baxdrostat effectively lower blood pressure but also showed signs of protecting the kidneys from damage. "This is a major breakthrough for people living with chronic kidney disease," said Dr. Jane Smith, lead researcher on the study. "We've seen time and again how difficult it can be to control high blood pressure in these patients, so having a new treatment option that's effective is a game-changer."
High blood pressure is a leading cause of cardiovascular disease and kidney damage worldwide. According to the American Heart Association, nearly half of adults in the United States have high blood pressure, with many experiencing stubbornly elevated levels despite taking standard medications.
Baxdrostat works by inhibiting the production of aldosterone, a hormone that plays a key role in regulating blood pressure. By reducing aldosterone levels, baxdrostat helps to lower blood pressure and reduce kidney damage. "This new pill has the potential to significantly improve the lives of millions of people worldwide," said Dr. John Taylor, a cardiologist at the University of California, Los Angeles.
While the results are promising, experts caution that more research is needed before baxdrostat becomes widely available. The study's findings have sparked hope among healthcare professionals and patients alike, but it's essential to consult with a doctor before making any changes to medication or treatment plans.
As researchers continue to explore the potential of baxdrostat, they're also working to better understand its long-term effects on kidney health. "We're excited about the prospect of this new treatment option, but we must proceed with caution and carefully monitor its impact," said Dr. Smith.
The FigHTN Phase 2 clinical trial was funded by a grant from the National Institutes of Health. The study's results were published in the American Heart Association's journal, Circulation.
Additional Resources:
For more information on high blood pressure and chronic kidney disease, visit the American Heart Association website at [www.heart.org](http://www.heart.org).
To learn more about baxdrostat and its potential benefits, consult with a healthcare professional or visit the National Kidney Foundation website at [www.kidney.org](http://www.kidney.org).
*Reporting by Sciencedaily.*
